Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report

Lung adenocarcinoma is the most common pathological pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. In the present clinical practice, antagonists of the epidermal growth factor receptor (EGFR) and vascular endothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Yanmei, Cui, Huijuan, Liu, Zhe, Liu, Daiwei, Liu, Fan, Song, Yazhong, Duan, Hua, Qiu, Yuqin, Li, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414636/
https://www.ncbi.nlm.nih.gov/pubmed/28490886
http://dx.doi.org/10.2147/OTT.S130990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414636/
https://www.ncbi.nlm.nih.gov/pubmed/28490886
http://dx.doi.org/10.2147/OTT.S130990

Ejemplares similares